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CVI988/Rispens  vaccine,  the  ‘gold  standard’  vaccine  against  Marek’s  disease  in  poultry,  is not  easily  distin-
guishable  from  virulent  strains  of Marek’s  disease  herpesvirus  (MDV).  Accurate  differential  measurement
of  CVI988  and  virulent  MDV  is  commercially  important  to  conﬁrm  successful  vaccination,  to diagnose
Marek’s  disease,  and  to investigate  causes  of vaccine  failure.  A  real-time  quantitative  PCR  assay  to  dis-
tinguish  CVI988  and  virulent  MDV  based  on  a consistent  single  nucleotide  polymorphism  in  the  pp38
gene,  was  developed,  optimised  and  validated  using  common  primers  to amplify  both  viruses,  but  dif-
ferential  detection  of  PCR  products  using  two  short  probes  speciﬁc  for either  CVI988  or virulent  MDV.
Both  probes  showed  perfect  speciﬁcity  for three  commercial  preparations  of  CVI988  and  12 virulent  MDV
strains.  Validation  against  BAC-sequence-speciﬁc  and  US2-sequence-speciﬁc  q-PCR,  on  spleen  sampleseal-time PCR
p38
ingle nucleotide polymorphism
from  experimental  chickens  co-infected  with  BAC-cloned  pCVI988  and  wild-type  virulent  MDV,  demon-
strated  that  CVI988  and virulent  MDV  could  be  quantiﬁed  very  accurately.  The  assay  was  then  used  to
follow  kinetics  of replication  of commercial  CVI988  and  virulent  MDV  in  feather  tips and  blood  of vac-
cinated  and  challenged  experimental  chickens.  The  assay  is  a great  improvement  in enabling  accurate
differential  quantiﬁcation  of  CVI988  and  virulent  MDV  over  a biologically  relevant  range  of virus  levels.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
Marek’s disease (MD) is a highly infectious lymphoid neo-
lasm of chickens caused by oncogenic serotype-1 strains (MDV-1)
f Marek’s disease virus (family Herpesviridae, subfamily Alpha-
erpesvirinae, genus Mardivirus). Susceptible breeds of chicken
evelop visceral and neural lymphomatous lesions (Baigent and
avison, 2004; Calnek, 2001), resulting in death or carcass condem-
ation. This economically important disease has been successfully
ontrolled since the 1970s by vaccination using cell-associated
Abbreviations: 40-Ct, cycle threshold value in real-time PCR subtracted from 40;
AC, bacterial-artiﬁcial-chromosome; dpc, days post challenge; dpv, days post vac-
ination; FAM-BHQ1, probe with carboxyﬂuorescein (FAM) reporter ﬂuorochrome
nd  Black Hole Quencher; LOD, limit of detection by q-PCR; ovo, chicken ovotrans-
errin gene; PBL, peripheral blood lymphocytes; pp38-CVI, PCR probe speciﬁc for
VI988 pp38 gene sequence; pp38-Vir, PCR probe speciﬁc for virulent MDV  pp38
ene sequence; q-PCR, real-time quantitative polymerase chain reaction; SNP, single
ucleotide polymorphism; YY-TAMRA, probe with Yakima Yellow reporter ﬂuo-
ochrome and tetramethylrhodamine quencher.
∗ Corresponding author.
E-mail addresses:
ue.baigent@outlook.com (S.J. Baigent), venugopal.nair@pirbright.ac.uk (V.K. Nair),
erve.Legalludec@zoetis.com (H. Le Galludec).
ttp://dx.doi.org/10.1016/j.jviromet.2016.03.002
166-0934/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
live avirulent and nononcogenic vaccine strains of all three
Mardivirus serotypes. Serotype 2 (MDV-2) or serotype 3 (her-
pesvirus of turkeys, HVT) vaccine viruses are naturally avirulent
in chickens (Okazaki et al., 1970; Schat and Calnek, 1978), while
CVI988/Rispens vaccine (de Boer et al., 1986; Rispens et al., 1972) is
a naturally-attenuated MDV-1 strain. MD vaccine viruses establish
persistent infection and lifelong immunity, effectively protecting
against tumours and mortality. However, vaccination does not pre-
vent superinfection, replication and shedding of virulent challenge
viruses (Davison and Nair, 2005; Gimeno, 2008), so chickens can
potentially be infected simultaneously with both vaccine and vir-
ulent MDV  strains.
Accurate differential measurement of vaccine and virulent virus
in the same individual chicken is both commercially important
and experimentally useful. In the ﬁeld, it could conﬁrm success-
ful vaccination and assist in identifying causes of vaccine failure,
such as administration of a sub-optimal vaccine dose (Landman
and Verschuren, 2003), interference with vaccine virus replication
by maternal antibodies (King et al., 1981; de Boer et al., 1986), and
infection with virulent MDV  ﬁeld strains (Witter et al., 2005). In
the laboratory, it could be used to study mechanisms of vaccinal
protection and differences in efﬁcacy between vaccines.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Therefore, it is important to have a reliable test for differentia-
ion of MDV-infected and vaccinated animals (DIVA test). Real-time
uantitative polymerase chain reaction (q-PCR) is a sensitive and
peciﬁc molecular diagnostic method. Serotype-speciﬁc q-PCR can
e used to distinguish and differentially quantify MD  vaccine and
hallenge virus, where vaccine is of serotype 2 (Islam et al., 2004;
enz et al., 2006) or serotype 3 (Islam et al., 2004, 2006a,b), and
hus of a different serotype to challenge virus (always serotype
). CVI988 is the ‘gold standard’ vaccine against MD because it
s antigenically and genetically 98% identical to virulent strains
Spatz et al., 2007a), and therefore elicits a very effective immune
esponse. However, the downside of this is that CVI988 is not easily
istinguishable from virulent MDV-1, restricting the application of
ifferential molecular diagnostics (Baigent et al., 2006b). To date,
evelopment of a q-PCR assay which is both accurately quantita-
ive and able to universally distinguish all virulent MDV  strains
rom CVI988, has not been possible.
Using bacterial-artiﬁcial-chromosome (BAC) cloned CVI988
irus (pCVI988), which carries the BAC vector sequences in place of
he MDV-1 US2 gene, q-PCR assays for differential quantiﬁcation of
CVI988 from virulent MDV  (by targeting the BAC vector sequence
nd the US2 gene respectively) were developed previously (Baigent
t al., 2011). Although these assays allowed investigation of repli-
ation of both pCVI988 vaccine virus and virulent MDV-1 in
xperimental infections (Baigent et al., 2011), they cannot be used
n the ﬁeld as commercial CVI988 does not contain a BAC sequence.
owever, the BAC-US2 q-PCR system, and the DNA samples gen-
rated in that study, represents an ideal system against which
o validate any prospective CVI988-speciﬁc and virulent MDV-1-
peciﬁc q-PCR assays.
Spatz and Silva (2007) identiﬁed several types of sequence dif-
erence in the repeat long (RL) genomic regions of 13 MDV-1 strains
f varying virulence: polynucleotide sequence expansions, short
andem repeat polymorphisms, sequence deletions, frameshift
utations and single nucleotide polymorphisms (SNPs). The efforts
f other researchers to develop DIVA PCR assays for CVI988 and
irulent MDV  have focused on the polynucleotide sequence expan-
ion of the 132-bp repeat region, the 177-bp insertion of duplicated
equence in the CVI988 meq  gene, and SNPs in the pp38 gene. Con-
entional PCR to amplify the 132-bp repeat region (Becker et al.,
992; Silva, 1992) could distinguish CVI988 from virulent MDVs
ased on a difference in the number of 132-bp repeats, but had
elatively low sensitivity (Davidson et al., 2002). A highly sensitive
uantitative meq gene q-PCR, that detects both CVI988 and virulent
DV  (Baigent et al., 2005a), can be used to quantify either CVI988
r virulent MDV  if only one of those viruses is present (Baigent
t al., 2005a,b, 2006a,b), or can be paired with the 132-bp repeat
CR to assist with distinction between CVI988 and virulent MDV  in
ixed infections. However, 132-bp repeat PCR is not very sensitive
or CVI988 (since the multiple bands of the CVI988 PCR products
ave much lower intensity than the single/double bands of the vir-
lent MDV  PCR products), not absolutely conclusive (Baigent et al.,
005b; van Iddekinge et al., 1999; Niikura et al., 2006; Petherbridge
t al., 2003; Silva and Gimeno, 2007), laborious, and the repetitive
ature of the 132-bp repeat region precludes its use as a quantita-
ive assay.
The meq  gene is polymorphic, with variation in the number of
equence repeats in the proline-rich region (Chang et al., 2002).
urata et al. (2007) developed a non-quantitative nested PCR to
istinguish between standard meq and large (L-)meq (with a 177-bp
nsertion). However, while virulent MDV  strains have standard meq,
VI988 may  have either L-meq or standard meq  (Lee et al., 2000), so
he 177-bp insertion is not a reliable differential marker for CVI988
nd virulent MDV. Based on a stable polymorphism in the meq gene,
enz et al. (2013) developed two sensitive and speciﬁc real-time
CRs to differentiate and accurately quantify 20 Australian viru-al Methods 233 (2016) 23–36
lent MDV  isolates and three commercial CVI988 vaccines used in
Australia. However, virulent isolates from USA, Asia and Europe do
not differ from CVI988 at this polymorphism so, while this assay
could be very successfully used in Australia, it could not be used
globally (Renz et al., 2013).
The MDV-1 pp38 gene has a SNP at base #320, which is con-
sistent between CVI988 (which has ‘G’ at this position) and all
sequenced virulent strains (which have ‘A’) (Cui et al., 1991; Endoh
et al., 1994; Spatz et al., 2007a,b). The current study therefore inves-
tigated the possibility of using SNP #320 as a reliable biomarker
for differentiating and quantifying CVI988 and virulent strains by
real-time PCR (pp38 SNP q-PCR assay). Subsequent to development
of this assay, Gimeno et al. (2014) published a real-time PCR assay
also based on SNP #320. However, their assay differs from the assay
reported in the current paper in terms of the molecular methods
used to amplify and detect the polymorphism, their ability to fully
validate the assay, and its quantitative accuracy.
The aims of the current work were (1) to design and optimise a
q-PCR assay based on SNP #320 in the pp38 gene to speciﬁcally
distinguish CVI988 from virulent MDV-1 strains; (2) to investi-
gate the feasibility of making this assay accurately quantitative
over a biologically relevant range of virus levels; (3) to validate
the assay against the BAC/US2 q-PCR assay; and (4) to use the assay
to investigate replication of CVI988 and virulent MDV  in tissues of
vaccinated, challenged experimental chickens.
2. Materials and methods
2.1. Design of q-PCR primers and probes
Primers and probes were designed by AlleLogic Biosciences Corp
(Hayward, CA). Primer and TaqMan® probe sequences, and their
location within the pp38 gene, are shown in Fig. 1. The forward and
reverse primers (pp38-FP and pp38-RP) are common to both the
CVI988 and virulent MDV-1 pp38 sequences, and the 99-bp ampli-
con covers the polymorphic region within which the probes were
designed. One 15-mer probe (pp38-Generic) was designed to target
a region common to all MDV-1 strains. Two  15-mer probes were
designed to incorporate the consistent G/A SNP #320, one speciﬁc
for the CVI988 sequence (pp38-CVI), and one speciﬁc for the vir-
ulent MDV-1 sequence (pp38-Vir(1)). Subsequently, an additional
probe (pp38-Vir(3)) was designed for detection of virulent MDV-
1, to have a melting temperature similar to that of the pp38-CVI
probe and the pp38-Generic probe. Probe pp38-Vir(3) also incor-
porates the ‘non-consistent’ SNP #326, so it is possible that afﬁnity
for some ﬁeld strains may  be reduced. However, in this study, the
speciﬁcity of pp38-Vir(1) and pp38-Vir(3) was  identical, but pp38-
Vir(3) was chosen as the probe for routine detection of virulent
MDV-1 because it was  more sensitive. Each probe was  labelled
with 5′FAM reporter, and 3′BHQ1 quencher. All probes were used
in combination with the same primer pair. All primers and probes
were manufactured by Sigma Genosys (UK).
2.2. DNA samples from virus stocks and chicken tissues
HVT strain FC126, MDV-1 strain HPRS-B14, and USA MDV-1
strains 675A, 584A, 648A, 660A, 595, Md5, 549, 571, JM102/W
(Witter, 1997; Witter et al., 2005) were obtained from Dr. A.M.
Fadly (Avian Disease and Oncology Laboratory, USA) all as 7th
duck embryo ﬁbroblast passage stocks. MDV-1 strain RB-1B was
prepared as previously described (Baigent et al., 2007). Euro-
pean MDV-1 isolate C12/130 (Barrow and Venugopal, 1999) was
prepared as previously described (Smith et al., 2011). Three com-
mercial CVI988 vaccine stocks were used: Pﬁzer Poulvac Marek CVI,
Merial BioMarekR, and Intervet Nobilis Rismavac. MDV-2 strain
S.J. Baigent et al. / Journal of Virological Methods 233 (2016) 23–36 25
ATGGAATTCGAAGCAGAACACGAAGGGCTGACGGCGTCTTGGGTCGCCCCCGCTCCCCAGGGTG
GAAAAGGGGCGGAGGGCCGCGCAGGGGTCGCCGACGAGGCAGGGCATGGGAAAACAGAAGCGGA
ATGCGCCGAGGACGGCGAGAAATGCGGGGACGCCGAGATGAGCGCTTTGGATCGGGTCCAGAGG
GACCGGTGGAGATTCAGTTCTCCGCCCCCTCACTCTGGAGTCACGGGGAAGGGGGCTATTCCAA
TAAAGGGTGATGGGAAGGCGATAGAATGCCAGGAGCTAACCGGAGAGGGAGAGTGGCTGTCACX
GTGGGYGGAGCTACCGCCTGAGCCCCGGAGGTCAGGGAATGAACATCTTGACGAAAGTCGGTAT
GCGAAACAAACCGAAAGGGGTAGCTCTACGGGGAAAGAAGAGGGAGATGGTATGAAGCAGATGG
GGGAGCTTGCCCAGCAGTGCGAAGGAGGAACATATGCGGACTTGCTTGTCGAAGCAGAGCAAGC
TGTTGTACATTCCGTTCGCGCATTAATGCTGGCCGAAAGACAAAACCCAAATATATTGGGGGAG
CATTTGAATAAAAAACGGGTTCTTGTACAACGACCCCGTACTATTCTATCCGTGGAGTCAGAGA
ATGCAACAATGCGTTCTTATATGCTGGTTACATTGATCTGTTCTGCAAAATCATTATTACTAGG
ATCGTGCATGTCATTTTTCGCTGGTATGTTAGTCGGTAGAACGGCAGACGTAAAAACACCATTA
TGGGATACTGTATGTTTGTTAATGGCTTTCTGTGCAGGCATTGTCGTTGGGGGAGTGGATTCTG
GGGAGGTGGAATCTGGAGAAACAAAATCTGAATCAAATTAA
Fig. 1. Location of primers and probes in MDV-1 pp38 gene sequences.
The pp38 gene sequence shows two single nucleotide differences (G/A SNPs) between CVI988 and Md5  (a representative virulent strain). The bold SNP X (#320) rep-
resents  a consistent difference between CVI988 and virulent strains. The bold italicised SNP Y (#326) is not consistent in all virulent strains. Sequences of the primers
(underlined text) were: forward primer 5′-GAGCTAACCGGAGAGGGAGA-3′ , and reverse primer 5′-CGCATACCGACTTTCGTCAA-3′ , and the amplicon size was 99 bp. Two 15-
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eer  probes (light grey shading), designed to the minus strand, covered the region
5′-CCCACTGTGACAGCC-3′ , Tm = 54.1). A third (17-mer) probe, pp38-Vir(3) includ
pp38-Generic, 5′-GCTACCGCCTGAGCC-3′ , designed to the plus strand, Tm = 57.4) w
B-1 was a commercial vaccine stock (SB-vacc, Intervet). pCVI988
irus was prepared from the BAC clone of Poulvac CVI988 DNA, as
reviously described (Petherbridge et al., 2003). All viruses were
repared as cell-associated stocks grown in chicken embryo ﬁbro-
last cells (CEF). For each virus stock, DNA was prepared from
pproximately 5 × 106 cells using the DNeasy-96 kit (Qiagen),
ccording to the manufacturer’s instructions. Chicken tissue DNA
amples were available from a previous study from experimental
hickens vaccinated with pCVI988 and/or challenged with virulent
train RB-1B (Baigent et al., 2011).
.3. Real-time quantitative PCR
Reactions were set up on ice, in 96-well plates in a PCR-
edicated cabinet, using PCR-dedicated pipettes and aerosol
esistant autoclaved tips. A master-mix was prepared diluting the
omponents in water, and 21 l aliquotted per reaction, so that
ach reaction contained: primers pp38-FP and pp38-RP (0.4 M),
ne of the above pp38 probes (0.2 M)  and ABsolute Blue® q-PCR
ow Rox master-mix (Thermoﬁsher UK). Duplex reactions to detect
oth pp38 and the chicken ovotransferrin (ovo) gene also contained
vo forward and reverse primers (0.4 M),  and ovo probe (0.2 M,
′Yakima Yellow-3′TAMRA, Eurogentec), the sequences of which
ere reported previously (Baigent et al., 2005a). All reactions were
ade up to 25 l by the addition of 4 l water (‘no template control’
ells), test DNA, standard DNA or control DNA. Every run included
B-1B DNA control (positive control for virulent MDV  detection
nd negative control for CVI988 detection) and CVI988 DNA con-
rol (positive control for CVI988 detection and negative control for
irulent MDV  detection) to ensure correct setting of the threshold.
-PCRs targeting the BAC and US2 gene sequences were performed
s previously described (Baigent et al., 2011). Standard curves were
repared using 10-fold serial dilutions of DNA from RB-1B-infected
EF (for pp38-Vir reaction and for US2 reaction), pCVI988-infected
EF (for pp38-CVI reaction and for BAC reaction) and non-infected
EF (for ovo reaction) all of which had been accurately calibrated
gainst plasmid constructs of known target gene copy number:
RB-1B (Petherbridge et al., 2004), pCVI988 (Petherbridge et al.,
003), and pGEMT-ovo (Baigent et al., 2005a). An ABI7500® system
Applied Biosystems) was used to amplify and detect the reaction
roducts, under the following conditions: 95 ◦C for 15 min, followed
y 40 cycles of 95 ◦C (15 s) and 60 ◦C (1 min). For chicken tissue DNA
amples, MDV  genomes were normalised to 2 × 104 copies of the
hicken ovo gene, so the standard curves enabled quantiﬁcation of
ach virus as genomes per 104 cells (Baigent et al., 2005a).ining SNP #320: pp38-CVI (5′-CCCACCGTGACAGCC-3′ , Tm = 57.7) and pp38-Vir(1)
th SNPs #320 and #326 (5′-CTCCCACTGTGACAGCC-3′ , Tm = 57.1). A fourth probe
argets a region common to pp38 of all MDV-1 strains, is shaded dark grey.
2.4. Quantitative accuracy of detection in virus mixtures.
Testing of sensitivity and quantitative accuracy of the pp38
q-PCRs, in mixed samples over a wide range of CVI988:virulent
MDV  ratios, was performed and validated against BAC-speciﬁc
and US2-speciﬁc q-PCRs, as described below. DNA prepared from
CEF infected with pCVI988 virus, and DNA prepared from CEF
infected with RB-1B was used to prepare dilution series. The start-
ing concentration of each DNA sample was  approximately 5 × 105
genomes per 4 l. DNA of pCVI988 was  diluted in DNA of RB-1B or
in DNA from non-infected CEF, in two  parallel dilution series; and
DNA of RB-1B was  diluted in DNA of pCVI988 or in DNA from non-
infected CEF, in two  parallel dilution series. Dilutions were 1:2, 1:5,
1:10, 1:30, 1:102, 1:103 and 1:104, each in duplicate. The pp38 SNP
q-PCR was  validated by two  means: (1) Comparing measurements
from samples diluted in DNA from the other virus with measure-
ments from samples diluted in chicken DNA from non-infected
CEF; (2) Comparing measurements made by the pp38-CVI q-PCR
and the pp38-Vir q-PCR, with those made using BAC-speciﬁc and
US2-speciﬁc q-PCRs respectively.
2.5. Validation of pp38 q-PCR assays on chicken tissue samples
Spleen DNA samples from experimental chickens which had
been vaccinated with BAC-cloned CVI988 virus (pCVI988) and/or
challenged with RB-1B, were available from a previous study
(Baigent et al., 2011). In that study, pCVI988 vaccine virus and RB-
1B challenge virus were distinguished and speciﬁcally quantiﬁed
using TaqMan® q-PCR to measure a BAC-speciﬁc target sequence,
and the US2 gene target sequence, respectively. In the current work,
the spleen DNA samples from this study were subjected to pp38
SNP/ovo duplex q-PCR assays, using either pp38-CVI, pp38-Vir(3),
or pp38-Generic as the pp38 detection probe. The appropriate stan-
dard curves were used to calculate genome copy no. per 104 cells
for CVI988, RB-1B or total MDV-1, respectively.
2.6. Time-course of replication of commercial CVI988 vaccine and
RB-1B challenge virus in individual chickens
Thirty-two one-day-old speciﬁed pathogen-free, maternal-
antibody-free Rhode Island Red chickens were randomly allocated
to three experimental groups. All procedures were performed
according to the guidelines of the UK Home Ofﬁce. The study
was performed under a Project Licence issued by the UK Home
Ofﬁce and approved by the Ethical Review Committee at The Pir-
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right Institute. Vaccination and challenge were performed only
y trained persons in possession of a Personal Home Ofﬁce Licence
ermitting them to perform these procedures.
Chickens were vaccinated by subcutaneous administration of
ne commercial dose of Poulvac CVI988 (Pﬁzer Animal Health) at
ne day of age. Chickens were challenged at 8 days of age, by intra-
bdominal administration of 100 l dose containing 1000 pfu MDV
train RB-1B (Schat et al., 1982) prepared as previously described
Baigent et al., 2007). Group A (n = 8) received vaccine only, Group
 (n = 14) received challenge virus only, and Group C (n = 10) was
oth vaccinated and challenged. Group A initially had 10 chick-
ns, but two were ‘non-starters’ and were culled prior to challenge.
he greater number of chickens in Group B was intentional, since
t was expected that some would die in the ﬁrst two  weeks post
hallenge. The three groups were housed in separate animal rooms
hich were high efﬁciency particulate air-ﬁltered and maintained
t negative pressure. Every chicken was sampled by trained person-
el at ten time-points between -4 and 38 days post challenge (dpc),
quivalent to 3 and 45 days post vaccination (dpv). Peripheral blood
ymphocyte (PBL) and feather tip samples were collected and pre-
ared as previously described (Baigent et al., 2005a,b). Feather tips
ere collected from 10 dpv (3 dpc), the ﬁrst time-point at which
eathers were present in sufﬁcient size. DNA was prepared from
BL and feather tips using the DNeasy-96 kit (Qiagen), according
o the manufacturer’s instructions, and each DNA sample was sub-
ected to pp38 SNP/ovo duplex q-PCR assays, using either pp38-CVI
r pp38-Vir(3) as the pp38 detection probe. The appropriate stan-
ard curves were used to calculate genome copy no. per 104 cells
or CVI988 or RB-1B. Chickens were monitored daily for morbidity
nd mortality, and any chicken reaching the humane end-point was
ulled using a Schedule 1 method by trained persons. All surviving
hickens were culled at 46 dpv (39 dpc). Post mortem examination
as performed on every chicken.
.7. Statistical analyses
Statistical analyses were performed using Minitab v15. To vali-
ate the efﬁcacy of the pp38 SNP q-PCRs in quantifying CVI988 and
B-1B in virus mixtures, mean 40-Ct values for virus DNA diluted
n non-infected CEF DNA were compared with mean 40-Ct val-
es for virus DNA diluted in DNA of CEF infected with the other
irus, using analysis of variance. To investigate correlation between
enome copies calculated using the two q-PCR systems (BAC-US2
-PCR vs pp38 SNP q-PCRs), samples were compared in pairwise
ombinations using regression analysis. To examine the effect of
o-infection on replication of CVI988 vaccine and RB-1B challenge
iruses in PBL and feather tips, arithmetic mean values for virus
enome copy number and 95% conﬁdence intervals were deter-
ined using the log10 transformed copy number for each individual
ample, then back-transformed to obtain actual values for presen-
ation of results. Analysis of variance was performed to examine the
ffect of challenge with RB-1B on the level of CVI988 per 104 cells in
hickens from the two vaccinated groups, and the effect of vacci-
ation on the level of RB-1B virus per 104 cells in chickens from
he two challenged groups. This analysis was performed within
ach sampling time-point (not as a repeated measures analysis),
o sampling time was excluded as a factor in the model. Pairwise
omparisons were made using Tukey simultaneous tests.
. Results
.1. Speciﬁcity of CVI988-speciﬁc and virulent MDV-1-speciﬁc
p38 probes in singleplex reactionsFig. 2 shows the change in ﬂuorescence when pp38-CVI, pp38-
ir(3) and pp38-Generic probes were used in 40-cycle q-PCR using
00 ng DNA from either CVI988-infected CEF or RB-1B-infected CEFal Methods 233 (2016) 23–36
as a template. The pp38-CVI probe gave a large increase in ﬂuores-
cence with CVI988 DNA template, while increase in ﬂuorescence
with RB-1B DNA template was minimal (ﬂuorescence did not cross
the threshold line at the default setting of 0.2, thus the sample
is scored negative) (Fig. 2a). The pp38-Vir(3) probe gave a large
increase in ﬂuorescence with RB-1B DNA, and some increase with
CVI988 DNA (Fig. 2b). Raising the threshold to 0.6 ensured that
CVI988 was always scored negative in this assay and prevented
false positive results. The pp38-Generic probe gave a large increase
in ﬂuorescence with both RB-1B and CVI988, with a threshold set-
ting of 0.2 (Fig. 2c). None of the three probes gave any increase in
ﬂuorescence in no-template-control wells.
The speciﬁcity of the two  probes was then tested against tar-
get DNA samples from a range of Mardiviruses: HVT (serotype 3),
SB-1 (serotype 2), CVI988 vaccine from three different commercial
sources, and 12 virulent MDV-1 strains covering the spectrum of
virulence from virulent (v), very virulent (vv) to very virulent plus
(vv+) (Witter et al., 2005). Fig. 2d shows that, using a detection
threshold of 0.2 for pp38-CVI, this probe detected all three com-
mercial CVI988 preparations, but did not detect any of the virulent
MDV-1 strains, or HVT, or SB-1. Using a detection threshold of 0.6
for pp38-Vir(3), this probe detected all virulent MDV-1 strains, but
did not detect CVI988, HVT or SB-1. Using a detection threshold of
0.2, pp38-Generic probe detected all CVI988 and all virulent strains
of MDV-1, but did not detect HVT or SB-1.
3.2. Assay sensitivity, efﬁciency, linearity and reproducibility
The probes were tested in q-PCR assays using 10-fold serial
dilutions of DNA prepared from CEF infected with either RB-1B
or CVI988. Mean ampliﬁcation efﬁciencies, R2 values and limits of
detection (LOD) are summarised in Table 1. LOD is the value for
x (gene copy no.) when y (40-Ct value) = 0. Fig. 3 shows the repro-
ducibility of standard curves, across three independent q-PCR runs,
using pp38-CVI probe with serial dilutions of CVI988 DNA (Fig. 3a)
and pp38-Vir(3) probe with serial dilutions of RB-1B DNA (Fig. 3b).
The assays show good reproducibility, sensitivity, linearity, efﬁ-
ciency, and a wide dynamic range.
3.3. Duplex q-PCR for absolute quantiﬁcation of CVI988 and
virulent MDV-1
In order to use the pp38 SNP q-PCR assays for absolute quantiﬁ-
cation of vaccine and challenge virus in tissue samples (expressed
as virus genomes per 104 cells), it was necessary to use duplex reac-
tions to simultaneously measure either the CVI988 pp38 gene and
the ovo gene, or the virulent MDV-1 pp38 gene and the ovo gene.
The ovo probe was  labelled with YY-TAMRA so as to be detected
in a different channel to the pp38 probe ﬂuorescence. The ovo and
pp38 reactions were shown to proceed with the same efﬁciency
when used in duplex reactions as in singleplex reactions (data not
shown). The mean ampliﬁcation efﬁciency, R2 value and LOD for
the ovo reaction are shown in Table 1.
3.4. Quantitative accuracy of detection in virus mixtures
Since the pp38 SNP q-PCR assay uses a universal primer pair,
complementary to a conserved region of the pp38 gene, both
CVI988 and virulent strains of MDV  will be ampliﬁed from a mixed
population, and thus there is no reaction speciﬁcity at this level
(speciﬁcity is determined solely by probe binding). Therefore, when
both CVI988 and virulent MDV  target sequences are present, they
will compete for the same primers. If one virus is present at a high
level, and the other at only a low level, it is possible that competi-
tion for primers would prevent ampliﬁcation (and thus detection)
of the less abundant virus. The ability of the reactions to accurately
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Fig. 2. Speciﬁcity of probes for CVI988 and virulent MDV-1.
Change in ﬂuorescence (delta Rn) when pp38-CVI, pp38-Vir(3) and pp38-Generic probes were used in 40-cycle q-PCR using 100 ng DNA from either CVI988-infected CEF or
RB-1B-infected CEF as a template. The thick horizontal line with an arrowhead at each end is the threshold (default value 0.2). (a) pp38-CVI probe detects CVI988 DNA but
not  RB-1B DNA; NTC is no-template control. (b) pp38-Vir(3) probe detects RB-1B DNA, while the signal from the CVI988 PCR product is very low. By raising the threshold line
to  0.6, CVI988 is scored negative in this reaction. (c) pp38-Generic probe detects both CVI988 DNA and RB-1B DNA. (d) The speciﬁcities of pp38-CVI, pp38Vir-A(3) and pp38-
Generic  probes were tested against a range of Mardivirus strains in a 40-cycle q-PCR. The 40-Ct value (the cycle threshold value, Ct, subtracted from 40) is proportional to the
amount of target DNA present. A 40-Ct value of 0 indicates that ﬂuorescence did not cross the threshold, i.e. the probe did not bind to the PCR product. ‘att MDV1′ = attenuated
MDV-1,  vMDV1 = virulent MDV-1, vvMDV1 = very virulent MDV-1, vv+MDV1 = very virulent plus MDV-1.
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Table  1
q-PCR assay efﬁciency and reproducibility.
Primers Probe DNA template Slopea R2 valueb LODc
pp38-FP +pp38-RP pp38-CVI CVI988-infected CEF DNA 3.52 0.995 5.7
pp38-FP +pp38-RP pp38-Vir(1) RB-1B-infected CEF DNA 3.53 0.995 29.6
pp38-FP +pp38-RP pp38-Vir(3) RB-1B-infected CEF DNA 3.48 0.994 9.6
pp38-FP +pp38-RP pp38-Generic CVI988-infected CEF DNA 3.27 0.992 8.9
pp38-FP +pp38-RP pp38-Generic RB-1B-infected CEF DNA 3.59 0.995 7.4
Ovo-FP + Ovo-RP Ovo Non-infected CEF 3.58 0.982 1.1
a measure of ampliﬁcation efﬁciency (good efﬁciency is considered to be 90% [slope = 3.59] − 105% [slope = 3.21]).
b R2 coefﬁcient of determination, a measure of linearity.
c Limit of detection (copies of target gene).
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Fig. 3. Assay sensitivity, efﬁciency, linearity and reproducibility.
The probes were tested in q-PCR assays using serial dilutions of DNA extracted from CVI988-infected CEF or RB-1B-infected CEF. Mean 40-Ct values from triplicate assays,
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Rith  95% conﬁdence limits for the regression and the R2 value, are shown for (a) p
erial  dilutions of RB-1B CEF DNA. The underlying points for 40-Ct values from tripli
quares, black diamonds and grey triangles).
uantify both CVI988 and virulent MDV-1 in mixed samples was
xamined and validated against BAC-speciﬁc and US2-speciﬁc q-
CRs (which will distinguish cloned pCVI988 and RB-1B without
ny competition for reagents).
The BAC-speciﬁc q-PCR detected the same level of pCVI988 DNA,
hether the pCVI988 DNA was diluted into RB-1B CEF DNA or into
on-infected CEF DNA at each dilution (data not shown). The US2-
peciﬁc q-PCR detected the same level of RB-1B DNA, whether the
B-1B DNA was diluted into pCVI988CEF DNA or into non-infectedVI probe with serial dilutions of CVI988CEF DNA, and (b) pp38-Vir(3) probe with
ssays are shown using three different symbols to distinguish the three assays (open
CEF DNA at each dilution (data not shown). These assays conﬁrmed
that the dilution series were accurately prepared and directly com-
parable, and that there was  no competition for reagents in these
q-PCR assays. For the pp38-CVI q-PCR, 40-Ct values for pCVI988
DNA diluted in RB-1B CEF DNA were only slightly (≤1 Ct unit) lower
than those for pCVI988 DNA diluted in non-infected CEF DNA, at
dilutions down to 1:5 (Fig. 4a). At 1:10 and 1:30 the difference
was greater (2Ct units) and statistically signiﬁcant and, at dilutions
of 1:102, 1:103, the difference was 4–7 Ct units (p < 0.001). Thus,
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Fig. 4. Quantitative accuracy of detection in virus mixtures using pp38 SNP q-PCR assays.
DNA was prepared from CEF cells infected with pCVI988, and from CEF cells infected with RB-1B, and each was  diluted to approximately 5 × 105 virus genomes per 4 l. (a)
DNA  of pCVI988-infected CEF was diluted in DNA of RB-1B-infected CEF (open triangles) or in DNA from non-infected CEF (black squares). (b) DNA of RB-1B-infected CEF
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p38-Vir(3) probe. The ﬁgures show mean 40-Ct values with standard error bars fo
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t the greater dilutions, pCVI988 DNA could clearly be detected
ut not accurately quantiﬁed. At 1:104 dilution in RB-1B DNA, the
CVI988 DNA was barely detectable, despite still being present at
evels detectable by BAC q-PCR, showing that reagent competition
n the pp38 SNP q-PCRs reduces detection of pCVI988 DNA when
B-1B DNA is in >5-fold excess. For the pp38-Vir(3) q-PCR, the effect
f reagent competition on measured level of RB-1B was  signiﬁcant
rom 1:5 dilution in pCVI988 DNA (p < 0.01) and, although RB-1B
NA was still clearly detected at further dilutions, it would not be
ccurately quantiﬁable (Fig. 4b).
.5. Validation of pp38 SNP q-PCR assays on chicken tissue
amples
Spleen DNA samples from experimental chickens were avail-
ble from a previous study (Baigent et al., 2011) where the chickens
ere vaccinated at one day of age with BAC-cloned CVI988 virus
pCVI988) and/or challenged at 15 days of age with RB-1B, and four
hickens per group sacriﬁced to collect spleen at each of eight time-
oints between 4 and 34 dpv (equivalent to −10 dpc to 20 dpc).
hese DNA samples were now subjected to pp38 SNP/ovo duplex q-
CR assays to determine level of vaccine virus and challenge virusd CEF (black squares). Samples were run in q-PCR using either pp38-CVI probe or
licate dilution series and duplicate reactions (only upper error bars are shown, for
as genome copies per 104 cells. The calculated level of pCVI988
was compared with that previously determined using the BAC-
speciﬁc q-PCR assay (Baigent et al., 2011), and the level of RB-1B
was compared with that previously determined using the US2-
speciﬁc q-PCR assay (Baigent et al., 2011). The speciﬁcity of each
of the reactions was as expected for the four groups of chickens:
pCVI988 was detected only in the two vaccinated groups and RB-1B
only in the two  challenged groups. For each individual spleen DNA
sample, total MDV-1 genome copy no., determined using the pp38-
Generic probe, was  compared with that obtained from the additive
results from US2 and BAC reactions, and from the additive results
from pp38-CVI and pp38-Vir(3) reactions. Fig. 5 shows correlation
between levels of pCVI988 vaccine virus, RB-1B challenge virus,
and total MDV-1 measured by the two  q-PCR systems. There was a
highly signiﬁcant relationship between the level of pCVI988 mea-
sured by the two  q-PCR systems (p < 0.0001, Fig. 5a), and between
the level of RB-1B measured by the two  q-PCR systems (p < 0.0001,
Fig. 5b). There was  a highly signiﬁcant relationship between the
level of total MDV  measured by pp38-Generic, BAC + US2 and pp38-
CVI + pp38-Vir(3) (p < 0.0001 for each of the comparisons; Fig. 5c
and d). These data conﬁrm that pp38-CVI and pp38-Vir(3) reactions
show excellent speciﬁcity, and can be used to accurately quantify
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Fig. 5. Validation of pp38 SNP q-PCR assays against BAC and US2 q-PCR assays.
Each data point shows values for an individual chicken (log10 genomes per 104 cells). (a) Comparison of BAC q-PCR and pp38-CVI q-PCR to measure pCVI988 in
vaccinated/non-challenged and vaccinated/challenged birds (n = 74). (b) Comparison of US2 q-PCR and pp38-Vir(3) q-PCR to measure RB-1B in challenged/non-vaccinated
and  challenged/vaccinated birds (n = 79). (c) Comparison of pp38-Generic q-PCR with additive results from pp38-CVI and pp38-Vir(3) q-PCRs to measure total MDV-1 in all
vaccinated and/or challenged birds (n = 102). (d) Comparison of additive results from pp38-CVI and pp38-Vir(3) q-PCRs, with additive results from BAC and US2 q-PCRs to
measure total MDV-1 in all vaccinated and/or challenged birds (n = 102).
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VI988 vaccine and virulent MDV-1 in tissue samples containing
oth viruses in biologically relevant amounts.
.6. Time-course of replication of commercial CVI988 vaccine,
nd RB-1B challenge virus in individual chicks
Having demonstrated, in the above experiment, that pp38 SNP
-PCR can be used to accurately quantify CVI988 vaccine and viru-
ent MDV-1 in tissue samples containing both viruses in biologically
elevant amounts, a further experiment was performed to exam-
ne replication of RB-1B challenge virus in experimental chickens
accinated with one dose of commercial CVI988 vaccine. For each
ndividual chicken, mortality and presence of MD  lesions were
ecorded, and the level of CVI988 or RB-1B at each time-point was
etermined by pp38-CVI q-PCR and pp38-Vir q-PCR respectively.
or each chicken, the detection kinetics of vaccine or challenge
irus in PBL (Table 2) broadly correlated with detection kinetics
n feather tips (data not shown). CVI988 was detected only in vac-
inated chickens and RB-1B only in challenged chickens.
No death and no macroscopic MD lesions were observed in any
hicken in Group A (vaccinated only). Each of these chickens was
ositive in pp38-CVI q-PCR and showed a uniform response, with
igh early replication of CVI988. RB-1B replicated to high levels
n the PBL and feathers of non-vaccinated chickens (Group B). Ten
ut of 14 chickens (72%) developed the disease following RB-1B
hallenge, each of these having become RB-1B-positive by 13 dpc
n PBL. Mortality occurred in two phases: ‘Early mortality’, from 8 to
1 dpc, was associated with rapid onset paralysis (6 chickens); and
D tumour phase, 20–33 dpc (4 chickens). At the end of the trial,
hree surviving chickens (#2421, #2436 and #2440) had high RB-1B
evels and were observed to have small MD  tumours; these chickens
ould likely have succumbed to MD had the trial continued for a
urther two weeks. The fourth survivor (#2342) did not become
B-1B-positive until 20 dpc, and had no visible lesions.
In Group C (vaccinated and challenged), one chicken (10%)
eached humane end-point and was culled at 10 dpc. This bird was
egative for CVI988 but had high early levels of RB-1B, indicating
hat it had not been successfully vaccinated. In the nine surviv-
ng chickens CVI988 was readily detected and no MD  lesions were
bserved. In ﬁve of these chickens, RB-1B was not detected in either
BL or feather tips at any time-point. In the remaining four chick-
ns, replication of RB-1B was considerably delayed, and was at a
ow level. Thus, vaccination had a major inhibitory effect on the
eplication of RB-1B in PBL and feathers of most chickens.
The mean level of virus in feather tips and PBL was calculated
or CVI988 (Fig. 6a) and RB-1B (Fig. 6b) for each group at each time-
oint. In feathers the mean level of CVI988 was lower in the RB-1B
hallenged group than in the non-challenged group from 33 dpv
nly, but the effect of RB-1B was not signiﬁcant at any time-point.
n PBL the mean level of CVI988 was lower in the RB-1B challenged
roup throughout the course of the experiment, this difference
eing signiﬁcant from 17 dpv onwards (p < 0.05). Vaccination with
VI988 signiﬁcantly lowered the mean level of measured RB-1B
t 6 dpc and all time-points thereafter, in both PBL (p < 0.001) and
eathers (p < 0.001).
. Discussion
It has been a long-term goal to have a reliable test for differential
uantiﬁcation of CVI988 vaccine and virulent MDV-1 in chickens,
ince this is commercially important to conﬁrm successful vacci-
ation, to investigate causes of vaccine failure and to conﬁrm a
iagnosis of MD.  To date, development of a q-PCR assay which is
oth accurately quantitative, and able to universally distinguish all
irulent MDV  strains from CVI988, has not been possible.al Methods 233 (2016) 23–36 31
The current work resulted in development, optimisation and
validation of an SNP-based real-time PCR assay which was speciﬁc,
sensitive, efﬁcient, reproducible, free from false-positive results,
and enabled accurate differential quantiﬁcation of CVI988 and
American and European virulent MDV-1 strains, over a biologically
relevant range of virus levels. The assay therefore offers several
advantages over previously published differential assays.
It was necessary to identify both a suitable genetic difference on
which to base the assays, and a suitable technology to enable quan-
titative differential detection of the difference. The selected genetic
difference was a consistent SNP at position #320 in the MDV-1 pp38
gene, and the selected technology involved use of unconventionally
short (15–17 nucleotide) TaqMan® probes.
The pp38 gene sequences have now been determined for over 40
virulent isolates of MDV  (NCBI database). The pp38 gene sequence
is identical in all MDV-1 strains with the exception of bases #320
and #326 (Cui et al., 1991; Endoh et al., 1994; Spatz et al., 2007a,b),
which differ between CVI988 and virulent strains. The polymor-
phisms result in a TspI restriction enzyme site in the pp38 gene
of all MDV-1s except CVI988, and different antibody epitopes (Cui
et al., 1999; Lee et al., 2005; Zhizhong et al., 2004), both of which
may  be used to differentiate CVI988 from virulent strains. At SNP
#326, CVI988 has ‘G’ and the majority of virulent strains have ‘A’;
however, some ‘atypical’ virulent strains (including GA strain, 571
strain, three Chinese strains and six recent Pennsylvanian ﬁeld
isolates) have ‘G’ and so SNP #326 cannot be used to reliably
distinguish virulent strains from CVI988 (Gimeno et al., 2014). Con-
versely, SNP #320 is consistent between CVI988 (which has ‘G’
at this position) and all sequenced virulent strains (which have
‘A’) (Gimeno et al., 2014; Spatz et al., 2007a). Based on this poly-
morphism, Dunn et al. (2010, 2012) developed pyrosequencing
assays to distinguish and semi-quantify recombinant viruses (that
had either the virulent-speciﬁc or CVI988-speciﬁc pp38 gene) in
virus super-infection and competition experiments. Although assay
speciﬁcity was  100%, sensitivity was relatively poor.
The current study therefore sought to investigate the possibility
of using SNP #320 as a reliable biomarker for differential quantiﬁ-
cation of CVI988 and virulent MDV  by real-time PCR. Real-time PCR
technology for differential detection of SNPs is now widely used, but
this only allows conﬁrmation that the virus in question is present
or absent, without quantiﬁcation. The goal was achieved by using
short TaqMan® probes to differentially detect PCR products follow-
ing ampliﬁcation with common primers. Short probes can improve
SNP detection by increasing quenching efﬁciency and speciﬁcity
of PCR product detection. Probe pp38-Vir(3) also incorporates the
‘non-consistent’ SNP #326, in order to have a melting temperature
similar to that of the pp38-CVI and pp38-Generic probes. This probe
was chosen for use in the current work because (for all of the viru-
lent MDVs tested here) it showed identical speciﬁcity, but greater
sensitivity than the probe which contains only SNP #320. When
these probes were ﬁrst designed, atypical MDV  ﬁeld strains having
‘G’ at #326 had been observed only very rarely (Spatz et al., 2007a).
However, since completion of these studies, several atypical strains
have been identiﬁed in some regions of the USA (Gimeno et al.,
2014) raising concerns that such strains are becoming increasingly
prevalent. Using probe pp38-Vir(3) could therefore pose problems
for the analysis of atypical ﬁeld isolates: there is a possibility that
such strains will not be efﬁciently detected by probe pp38-Vir(3)
containing SNP #326 (whereas they would be efﬁciently detected
using probe pp38-Vir(1) containing only SNP #320). The current
work included one atypical MDV  (strain 571) which was  detected
by both probes pp38-Vir(3) and pp38-Vir(1) with equal sensitiv-
ity, speciﬁcity and efﬁciency, which is reassuring. However, it will
be important to test more atypical strains with both probes and,
should issues with sensitivity, speciﬁcity and efﬁciency of probe
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Table  2
Measurement of CVI988 vaccine and RB-1B challenge virus in PBL of experimental chickens, using pp38 SNP q-PCR assay.
Group Bird # Virus Sampling time-point: PBL (virus level: genome copies per 10,000 cells) Survived S/Died D
(time of death dpc)
3 dpv 6 dpv 10 dpv 13 dpv 17 dpv 24 dpv 27 dpv 33 dpv 40 dpv 45 dpv
−4 dpc −1 dpc 3 dpc 6 dpc 10 dpc 17 dpc 20 dpc 26 dpc 33 dpc 38 dpc
A
Vacc only (level of CVI) a
2428 CVI —c 66 81 43 101 85 79 135 144 NDd S
2433  CVI – 7 36 31 40 21 15 23 22 18 S
2434  CVI – 74 75 53 75 57 56 42 10 31 S
2437  CVI 12 84 110 78 69 93 105 115 137 134 S
2442  CVI – 12 77 48 45 54 42 38 54 47 S
2444  CVI – 23 61 29 29 44 31 37 40 35 S
2446  CVI – 42 9 ND 24 34 15 16 15 9 S
2447  CVI – 17 192 52 151 129 91 89 92 113 S
B
Chall  only (level of
RB-1B) b
2401 RB1B – – 3.1 913 13231 15924 30017 De D D D 20 dpc
2403  RB1B – – – 133 3138 D D D D D D 11 dpc
2405  RB1B – – – 249 D D D D D D D 8 dpc
2421  RB1B – – – 336 6586 2968 3783 7878 16290 32241 S
2424  RB1B – – – 309 D D D D D D D 10 dpc
2429  RB1B – – 57 1421 D D D D D D D 8 dpc
2432  RB1B – – – – – – 4 17 1270 – S
2435  RB1B – – – 35 1528 1739 2632 3491 9352 D D 33 dpc
2436  RB1B – – – 73 2171 2881 5375 5391 4592 4902 S
2439  RB1B – 1.1 2.8 190 3631 4170 8707 D D D D 24dpc
2440  RB1B – – – 99 4400 2532 3893 6842 7983 14220 S
2443  RB1B – – 4.0 225 2493 8329 16123 D D D D 21 dpc
2445  RB1B – – 23 697 D D D D D D D 8 dpc
2448  RB1B – – – 419 D D D D D D D 8 dpc
C
Vacc  & Chall (level of
CVI and level of RB-1B)
2404 CVI – 10 98 31 18 9 12 12 9 7 S
RB1B – – – – – – – – – 87
2407 CVI – 12 44 22 7 12 11 10 11 21 S
RB1B – – – – – – – – – –
2414 CVI – 12 53 26 34 32 28 41 50 108 S
RB1B – – – – – – – – – –
2417 CVI – 6 25 4 5 2 2 0.3 0.3 1 S
RB1B – – – – – – – – – –
2418 CVI – 3 28 33 24 29 25 21 15 24 S
RB1B – – – – – – – – – –
2419 CVI – 6 7 10 11 8 16 9 7 12 S
RB1B – – – – – – – – – –
2420 CVI – – – – D D D D D D D 10 dpc
RB1B  – 0.9 0.9 460 D D D D D D
2422 CVI – 23 37 23 10 10 11 9 4 2 S
RB1B – – – – – 2 2 10 50 134
2423 CVI – 6 20 31 17 10 12 7 4 0.3 S
RB1B – – – – – – – – – 171
2425 CVI – 9 51 65 22 25 8 4 3 4 S
RB1B – – – – – – – – – 3
a All Group A birds were negative for RB-1B at each time-point (data not shown).
b All Group B birds were negative for CVI988 at each time-point (data not shown).
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lc —indicates samples that were considered negative in the q-PCR (40-Ct value ≤1
d ND = Not done (chicken inadvertently not sampled at this time-point).
e D = bird dead, therefore no sample at this time-point.
p38-Vir(3) be identiﬁed, it would be prudent to use only probe
p38-Vir(1) to test ﬁeld samples in the future.
Simultaneous to the current work on developing this assay,
imeno et al. (2014) sought to use the same polymorphism to
chieve the same goal. However, their assay differs from the assay
resented in this paper in terms of the molecular methods used to
mplify and detect the polymorphism, their ability to fully validate
he assay, and its quantitative accuracy. Speciﬁcity in real-time PCR
s ideally required at two levels: PCR product speciﬁcity (differen-
ial ampliﬁcation) and probe speciﬁcity (differential detection). The
Gimeno assay’ is based solely on differential ampliﬁcation, while
he current assay is based solely on differential detection. While
oth the current assay and the Gimeno assay have some com-
lementary advantages and disadvantages, the former represents
n improvement in that accurate differentiation and quantiﬁca-
ion has been validated over a biologically-relevant range of virus
evels. Gimeno et al. (2014) developed a Mismatch Ampliﬁcation resulted in a baseline value of 0.6 genome copies per 104 cells.
Mutation Assay, which incorporates an intentional mismatch at the
3′ penultimate position in the PCR primers, a recognized method
of increasing assay speciﬁcity. They used forward primers which
incorporated the SNP at the last base (a CVI988-speciﬁc primer and
a virulent MDV-speciﬁc primer) and a generic reverse primer, in a
non-probe (SYBR-green) real-time PCR. PCR assays using primers
designed to distinguish between a single nucleotide are frequently
very inefﬁcient. For this reason, the current work sought to develop
probe-based TaqMan® q-PCR using primers that would amplify
pp38 of both CVI988 and virulent strains, and to incorporate the
SNP into the short probes (a CVI988-speciﬁc probe and a virulent
MDV-speciﬁc probe).
When either CVI988 only or virulent MDV  only was present in
a DNA sample, both the Gimeno assay and the current assay were
highly speciﬁc and either virus could be accurately quantiﬁed over
a wide dynamic range using standard curves. Both assays were
reproducible and very sensitive but, while the limit of detection
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Fig. 6. Time-course of replication of commercial CVI988 vaccine and RB-1B challenge virus in individual chickens.
One-day-old Rhode Island Red chickens were divided between three experimental groups. Group A (n = 8) received CVI988 vaccine only, Group B (n = 14) received RB-1B
challenge virus only, and Group C (n = 10) was  both vaccinated and challenged. Feather and blood samples were collected from each chicken at regular intervals. DNA was
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ean  virus levels (with 95% conﬁdence intervals) for each group and each sample t
b).  Values of 0.6 (baseline value) are considered negative. Only upper conﬁdence in
n the current assay was approximately 10 copies of virus genome,
he Gimeno assay showed higher sensitivity detecting as little as
ne copy. Thus, both assays could successfully differentially detect
VI988 and virulent MDV.
However, both the current assay and the Gimeno assay had some
imitations when attempting to speciﬁcally and accurately quan-
ify CVI988 or virulent MDV  in mixtures of virus-infected cell DNA
current assay) or DNA of plasmid carrying an insert of the pp38
ene of either CVI988 or virulent MDV  (Gimeno et al., 2014) over a
ide range of genome copies. The Gimeno assay suffered from ‘false8 detection probe, and the level of each virus quantiﬁed as genomes per 104 cells.
 each time-point are shown for CVI988 vaccine virus (a) and RB-1B challenge virus
ls are shown for clarity.
positive’ results (loss of speciﬁcity if miss-matched sequence is in
excess), and was only accurately quantitative if the homologous
sequence was  present above a certain level, and the heterologous
sequence below a certain level. Conversely, the assay reported in
this paper had issues with ‘false negative’ results (always speciﬁc,
but loss of sensitivity if miss-matched sequence is in excess). This
assay has an additional level of speciﬁcity through use of probes
which each bound minimally to the miss-matched PCR product.
However, use of universal primers to amplify both CVI988 and vir-
ulent MDV  can yield false negatives since, in mixtures of CVI988
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nd virulent MDV  DNA, these two target sequences will compete for
rimers. Consistent with this, when DNAs from CVI988 and virulent
DV  were mixed over a wide range of ratios, competition for PCR
rimers by the predominant virus reduced the ampliﬁcation (and
hus detection) of the less abundant virus. Therefore, although the
ess abundant virus could still be detected, it could not be accurately
uantiﬁed when the other virus was predominant.
Field samples will contain CVI988 and virulent MDV-1 in vary-
ng ratios. Both the current study, and Gimeno et al. (2014),
alidated the respective assays using tissue samples from exper-
mental chickens which were either CVI988-vaccinated only,
vMDV-challenged only, or both CVI988-vaccinated and vvMDV-
hallenged. However, while Gimeno et al. (2014) used commercial
VI988 vaccine, the current study initially used BAC-cloned
VI988 vaccine which gave a signiﬁcant advantage in conﬁrmation
f reliable and conﬁdent validation, since the BAC-sequence-
peciﬁc/US2-sequence-speciﬁc q-PCR system (Baigent et al., 2011),
here there is no competition for primers, was used for valida-
ion of the pp38 SNP q-PCR assay. In the current study, use of the
p38-Generic reaction to validate the additive results of the virus-
peciﬁc assays showed that, over a biologically-relevant range of
VI988 and virulent MDV  levels generated in the in vivo challenge
odels used here, either virus could be quantiﬁed with a high level
f accuracy. When CVI988-vaccination was performed correctly
nd effectively, the immune response kept the challenge virus at
 level which was too low to impede accurate measurement of
VI988. Conversely, when CVI988 vaccination was not successful,
he level of CVI988 was too low to impede accurate measurement
f challenge virus.
The pp38 SNP q-PCR assay could therefore be used with conﬁ-
ence to follow kinetics of replication of commercial CVI988 and
B-1B in individual chickens. Mean kinetics of replication in PBL
nd feathers were consistent with previous reports for CVI988 in
on-challenged chickens (Baigent et al., 2005b) and RB-1B in non-
accinated chickens (Singh et al., 2010). Vaccination with CVI988
igniﬁcantly reduced or almost completely inhibited detection of
B-1B in PBL and feathers, consistent with the observations of Islam
t al. (2013, 2014) following challenge of CVI988-vaccinated chick-
ns with an Australian vvMDV strain and distinction between the
wo viruses using the Australian strain-speciﬁc meq q-PCR assays
Renz et al., 2013). The reduction in virulent MDV  load in CVI988-
accinated chickens is greater than that observed in either SB-1
accinated chickens (Singh et al., 2010), HVT-vaccinated chickens
Islam et al., 2006b; Walkden-Brown et al., 2013a), or MDV-2/HVT
ivalent-vaccinated chickens (Walkden-Brown et al., 2013a) con-
istent with the fact that CVI988 is the most effective vaccine. It was
nteresting that the mean level of CVI988 measured in PBL (but not
n feathers) was signiﬁcantly lower in the RB-1B challenged group
han in the non-challenged group, whereas Islam et al. (2014) found
hat challenge on or after 5 dpv had little effect on CVI988 load. The
ossibility that this result in the current study could be a false result,
eﬂecting competition for q-PCR reagents in samples containing
oth CVI988 and RB-1B reducing efﬁcacy of CVI988 detection, was
onsidered. However, given that the measured level of RB-1B was
ow in this group, it seems unlikely that such reagent competi-
ion had any marked effect on measurement of either CVI988 or
B-1B in these samples. Therefore, it is likely that challenge with
B-1B had a true effect on reducing replication of CVI988 under the
xperimental conditions used in the current study.
Prior to publication of validation of their assay by Gimeno et al.
2014), Haq et al. (2012) used this assay to examine replication of
VI988 vaccine and virulent challenge virus in feathers of experi-
ental chickens. Consistent with the results of the current study,
hey observed that challenge with virulent MDV  had no signiﬁcant
ffect on replication of CVI988 in feathers, but that vaccination with
VI988 reduced the level of RB-1B measured in feathers. This reduc-al Methods 233 (2016) 23–36
tion was more dramatic in the current study, but this may  reﬂect
differences in the vaccine used (Poulvac CVI988 vs Merial CVI988),
the age at which vaccination was performed (day-old vs in ovo), or
the fact that the Gimeno assay may  yield false positive results.
The in vivo challenge model used in the current work (using
chickens free of maternal antibody against MDV, a vaccination-
challenge interval of 7 days, and vvMDV strain RB-1B as the
challenge virus) did not result in any instance of the presence of rel-
atively high levels of both vaccine and challenge virus together in
an individual bird, and so there was no opportunity to demonstrate
that the assay could accurately differentially quantify relatively
high levels of co-infection in a chicken tissue sample. Use of a
vv+ challenge strain and shorter vaccination-challenge interval
might have resulted in higher levels of both viruses in the co-
infected group. However, the challenge model was carefully chosen
to aim for a balance between sufﬁcient replication of challenge
virus (to ensure that it still replicated in the CVI988-vaccinated
group) and sufﬁcient survival of chicks (to ensure multiple sam-
ples at multiple time-points for analysis). Inclusion of a challenged
but non-vaccinated control group was  necessary in order to observe
the effect of vaccination on reduction of challenge virus load, but
almost 50% of non-vaccinated chicks had died by 10 dpc. This early
mortality would have been exacerbated had a shorter vaccination-
challenge interval, and/or a vv+ challenge strain (Read et al., 2015)
been used, so sufﬁcient data would not have obtained from this
control group, although the co-infected group would likely have
had higher levels of both viruses. Use of chicks having maternal-
antibody against MDV  (to reduce the issues with early mortality),
combined with a higher dose of RB-1B challenge virus, might pro-
vide higher levels of CVI988/RB-1B co-infection, and this would be
interesting to examine.
The technology used in these MDV  q-PCRs could be applied to
other herpesvirus-induced diseases of man and animals, where live
attenuated vaccines are used but there are minimal genetic dif-
ferences between vaccine and virulent strains. Similar technology
is available for human Varicella Zoster Virus, where SNPs in ﬁve
genes identify four major subtypes and additional SNPs can dif-
ferentiate the live attenuated Oka vaccine strain from wild-type
strains (Quinlivan et al., 2005; Parker et al., 2006), but this was not
quantitative.
Live attenuated vaccines, with high genetic similarity to vir-
ulent strains, are used against infectious laryngotracheitis virus
(ILTV), another herpesvirus of chickens. Generation of new viru-
lent ILTV strains by recombination between two  attenuated vaccine
strains was recently demonstrated in Australia (Lee et al., 2012).
This potentially raises concerns for the long-term reliability of the
assay presented in the current work for distinguishing CVI988 from
virulent MDV. Given the now well-documented instability of the
polymorphism at position 326 (Gimeno et al., 2014; Spatz et al.,
2007a), how stable is the ‘consistent’ polymorphism at position
320 on which both this assay, and the Gimeno assay rely? Could
mutation, or recombination between CVI988 and virulent strains,
result in generation of new virulent viruses which have ‘G’ at posi-
tion 320 and are therefore detected by the CVI988-speciﬁc assay
and not by the virulent-speciﬁc assay? Although such viruses have
been generated in the laboratory by genetic engineering (Cui et al.,
1999; Lee et al., 2005) they have never been reported in the ﬁeld:
all virulent isolates sequenced to date, which have been isolated
over a period of 40 years and cover the whole virulence spec-
trum, have ‘A’ at position 320. Therefore, this can be considered a
highly stable polymorphism, so the pp38-Vir(1) probe should reli-
ably differentiate virulent strains from CVI988 in the long-term.
Nevertheless, should clinical signs of MD  be observed in the absence
of detection of any virus by the ‘virulent-speciﬁc’ assay, it would be
prudent to sequence the whole virus genome and to perform in vivo
pathogenicity studies in SPF chicks to further characterise the virus.
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In summary, the pp38 SNP q-PCR assay allows fast, reli-
ble, sensitive, speciﬁc and accurate differential quantiﬁcation of
VI988 vaccine and virulent MDV  in chicken tissue samples over
 biologically-relevant range of virus levels, and thus represents
n advance over currently available methods. In the commercial
nvironment, the assays could be exploited for conﬁrming success
f CVI988 vaccination, for monitoring circulation of virulent ﬁeld
trains and for diagnosis of MD,  using feather, blood or organ sam-
les; and for monitoring MDV  contamination of the poultry house
nvironment in samples of poultry dust (Walkden-Brown et al.,
013b; Baigent et al., 2013). Ultimately, use of the pp38-CVI, pp38-
ir(1) and ovo probes in a single triplex reaction could be optimised
o enable simultaneous quantiﬁcation of CVI988 and virulent MDV.
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